Evidence map›Paper›PMID 29968039›Full record

ArticleJournal of neuro-oncology2018

BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.

Keishi Makino, Hideo Nakamura, Naoki Shinojima, Jun-Ichiro Kuroda, Shigetoshi Yano, Yoshiki Mikami, Akitake Mukasa

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Keishi MakinoDepartment of Neurosurgery, Kumamoto University, 1-1-1 Honjo Chuo-ku, Kumamoto, 860-8556, Japan. kmakino@kuh.kumamoto-u.ac.jp.ORCID http://orcid.org/0000-0002-4607-2646
Hideo NakamuraDepartment of Neurosurgery, Kumamoto University, 1-1-1 Honjo Chuo-ku, Kumamoto, 860-8556, Japan.
Naoki ShinojimaDepartment of Neurosurgery, Kumamoto University, 1-1-1 Honjo Chuo-ku, Kumamoto, 860-8556, Japan.
Jun-Ichiro KurodaDepartment of Neurosurgery, Kumamoto University, 1-1-1 Honjo Chuo-ku, Kumamoto, 860-8556, Japan.
Shigetoshi YanoDepartment of Neurosurgery, Kumamoto University, 1-1-1 Honjo Chuo-ku, Kumamoto, 860-8556, Japan.
Yoshiki MikamiDepartment of Diagnostic Pathology, Kumamoto University Hospital, 1-1-1 Honjo Chuo-ku, Kumamoto, 860-8556, Japan.
Akitake MukasaDepartment of Neurosurgery, Kumamoto University, 1-1-1 Honjo Chuo-ku, Kumamoto, 860-8556, Japan.
Kumamoto University · JPKumamoto University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePrimary central nervous system diffuse large B-cell lymphoma (CNS-DLBCL) is a distinct clinicopathological entity with a poor prognosis. Concurrent MYC and BCL2 overexpression predicts inferior prognosis in systemic DLBCL, although their prognostic significance remains unclear in primary CNS-DLBCL.

methodsPretreatment diagnostic biopsy samples were retrospectively evaluated for 79 patients with primary CNS-DLBCL who were treated between January 2001 and December 2017. Histological and immunohistochemical testing were performed to evaluate the patients' statuses for various markers, which were also evaluated for associations with survival outcomes.

resultsAccording to the Hans criteria, 26 patients (32.9%) had the germinal center B-cell subtype and 53 patients (67.1%) had the activated B-cell subtype. Forty-one cases (51.9%) were positive for MYC (expression of ≥ 40%), 33 cases (41.8%) were positive for BCL2 (expression of ≥ 70%), 22 patients (27.8%) were positive for both MYC and BCL2, and 27 patients (34.2%) were negative for both MYC and BCL2. There were no significant differences in survival between the germinal center and activated B-cell subtypes. Furthermore, MYC positivity was not associated with overall survival (p = 0.369) or progression-free survival (PFS) (p = 0.253). However, BCL2 positivity was significantly associated with poor overall survival (p = 0.039) and PFS (p = 0.036). Co-expression of MYC and BCL2 was not associated with survival.

conclusionOur data suggest that evaluating BCL2 expression may help predict the prognosis in cases of primary CNS-DLBCL.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorB-LymphocytesCentral Nervous System NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryLymphoma, Large B-Cell, DiffuseMaleMiddle AgedPrognosisProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycBCL2 protein, humanBiomarkers, TumorMYC protein, humanProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycBCL2Cell of originImmunohistochemistryMYCPrimary central nervous system lymphoma

Identifiers

PMID29968039
OpenAlexW2810444639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.